ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression

AbbVie (ABBV) has acquired bretisilocin, Gilgamesh Pharmaceuticals' lead psychedelic candidate for major depressive disorder (MDD), for up to $1.2 billion, including an upfront payment and development milestones. This novel compound, currently in Phase II, demonstrated rapid, robust, and durable antidepressant effects in MDD patients, significantly reducing MADRS scores. The acquisition reinforces AbbVie's strategy to bolster its early-stage neuroscience pipeline, a segment that saw 20.3% sales growth in H1 2025, and signals continued investment despite recent setbacks with other neuroscience assets like emraclidine from the Cerevel acquisition.

Analysis

AbbVie is strategically deepening its investment in neuroscience by acquiring Gilgamesh Pharmaceuticals' lead candidate, bretisilocin, for up to $1.2 billion. This move reinforces its focus on building an early-stage pipeline, particularly within a therapeutic area that has become a key growth engine, with sales increasing 20.3% to approximately $5 billion in the first half of 2025. The acquired asset, bretisilocin, is a novel psychedelic for major depressive disorder that has demonstrated promising Phase II data, showing a statistically significant reduction in the MADRS score by 21.6 points versus 12.1 for the comparator. This acquisition, however, comes on the heels of a significant setback with emraclidine, a key asset from the prior Cerevel Therapeutics acquisition, which failed two registration-enabling studies. This contrast highlights the high-risk, high-reward nature of AbbVie's M&A strategy. Despite this recent failure, AbbVie's stock has outperformed its industry year-to-date, gaining 20.1% against the industry's 1.6% rise, though it currently holds a Zacks Rank #3 (Hold), suggesting a neutral analyst outlook.

Key Decisions for Investors

• Investors should view this acquisition as a long-term strategic bet to bolster AbbVie's pipeline in the high-growth neuroscience market, not as a near-term earnings contributor, given the early stage of the asset.
• The recent failure of the emraclidine program from the Cerevel deal underscores the significant clinical development risk in AbbVie's M&A strategy; therefore, progress and future data from bretisilocin's trials must be monitored closely to validate this new investment.
• While AbbVie's year-to-date stock performance is strong, the neutral 'Hold' rating and the mention of better-ranked peers like J&J and Bayer suggest it may be prudent to evaluate the company's risk profile against others in the large-cap pharma sector.